We are monitoring the impact of COVID-19 on Peptide Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date May, 2021
ID: 11600
Share on
Share on

Global Peptide Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type, Application, Type of Manufacturers, Route of Administration, Synthesis Technology & Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa)- Industry Forecast (2021 to 2026)

Pulished: May, 2021
ID: 11600
Pages: 190

Global Peptide Therapeutics Market Size (2021 to 2026)

The global peptide therapeutics market size is forecasted to be growing at a CAGR of 10.24% from 2021 to 2026.

Peptides are biological molecules that exist naturally and play an important role in many biological processes. When endogenous levels of peptide hormones continue to decrease, peptide drugs are used as substitution therapies. A peptide is a short chain of amino acids in which the amino acids are linked together in a series by peptide bonds. Peptides are highly complex signaling molecules that bind to specific cell surface receptors, including G Protein-Coupled Receptors (GPCRs) or ion channels, causing intracellular effects. In the nineteenth century, the first peptide therapeutic was used to treat diabetic patients. For cancer, metabolic diseases, and cardiovascular disease, these medications are used as drug target moiety.

Peptides are effective precursors in developing new therapeutics due to their inherent properties of specificity, safety, and tolerability and their ability to produce expected results in humans. If more hybrid technologies are introduced to achieve economies of scale, the global peptide therapeutics market is expected to develop. Furthermore, compared to traditional pharmaceutics, peptide therapeutics have greater effectiveness and clinical results with fewer side effects, increasing their popularity among patients and prescribers.

MARKET DRIVERS:

The growing developments in peptide therapeutics and the rising prevalence of metabolic disorders and infectious diseases drive the global peptide therapeutics market growth.

Peptide processing requires a low cost of production, and the demand for peptide therapeutics is expected to expand over the projected period due to an increase in clinical applications. Other factors increasing the market expansion are rising advances in research and production of new medicines and technical developments in peptide therapeutics. In addition, increased healthcare spending is also expected to help the peptide therapeutics market to expand.

The development of new peptides is expected to provide lucrative growth opportunities for industry players. Over the forecast period, the global peptide therapeutics market is expected to expand due to an increase in the prevalence of metabolic diseases and cardiovascular disorders (CVDs). Furthermore, peptide-based therapeutics have already shown to be a profitable sales opportunity for key manufacturers, so the global peptide therapeutics market is expected to expand in the coming years.

MARKET RESTRAINTS:

The global peptide therapeutics market growth is hindered by natural peptides' poor chemical and physical stability and low circulating plasma half-life. In addition, the low oral bioavailability of peptide drugs due to injection administration and poor intestinal mucosa penetration are likely to limit demand development in the near future.

The market development is further expected to limit by peptide therapeutics' instability, the high cost of manufacturing medicines, and strict regulatory criteria for drug approval. As a result, the cost of discovering and developing new therapeutics is high, and commercialization takes longer. In addition, long peptide purification has been challenging due to the reduced capability of solid-phase reactors for chemical fictionalization and resin swelling.

COVID-19 Impact on the global peptide therapeutics market:

COVID-19 is a worldwide pandemic caused by the coronavirus (SARS-CoV-2), a severe acute respiratory syndrome (SARS). People who had covid had respiratory issues. The use of peptide molecules in the development of the COVID-19 vaccine is expected to increase, boosting market growth. Peptides are attractive to pharmaceutical producers because they are simple to manufacture. Compared to the old trial-and-error method, today's approach begins with a thorough understanding of the disorder on a molecular basis. Then, experimental medicines are developed based on drug result predictions. Furthermore, extensive government support for the use of peptides in the formulation of the COVID-19 vaccine is expected to provide a potential catalyst for peptide adoption, potentially stimulating the growth of the peptide therapeutics industry.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Type, Type of Manufacturers, Application, Route of Administration, Synthesis Technology, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global peptide therapeutics market has been segmented and sub-segmented based on the product, distribution channel, and region.

Global Peptide Therapeutics Market – By Type:

  • Generic
  • Innovative

Based on the type, Due to increased investments by large pharmaceutical companies in R&D for the development of novel drugs and high prescription rates, Innovative peptides dominated and had the highest share.

Global Peptide Therapeutics Market – By Application:

  • Metabolic
  • Cardiovascular Disorder
  • Respiratory
  • GIT
  • Anti-infection
  • Pain
  • Dermatology
  • CNS
  • Renal
  • Others

Based on the application, the cancer segment dominates the market in terms of revenue generation. The primary drivers driving this segment's domination are an increase in the global prevalence of cancer and an increase in the prescription of peptide therapeutics for cancer therapy.

Global Peptide Therapeutics Market – By Type of Manufacturers:

  • In-house
  • Outsourced

Based on the type of manufacturers, the segment of In-house manufacturing had the most market share. Due to stringent restrictions and the expensive expense of outsourcing, most of the major players are developing peptide therapeutics in-house. In addition, large pharmaceutical businesses choose in-house manufacturing because they have the necessary infrastructure and technical technologies for large-scale production.

Global Peptide Therapeutics Market – By Route of Administration:

  • Parenteral Route
  • Oral Route
  • Pulmonary
  • Mucosal
  • Others

Based on the route of administration, in 2020, the Parenteral route segment had the largest market share; however, the oral segment is expected to grow at the fastest rate over the forecast period.

Global Peptide Therapeutics Market – By Synthesis Technology:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Based on Synthesis Technology, Because of the growing need for pure peptides to develop effective medicines, the Liquid Phase Peptide Synthesis (LPPS) segment led in 2020.

Global Peptide Therapeutics Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Over the forecast period, the North American peptide therapeutics market is predicted to account for the largest share globally during the forecast period. This is due to the increasing incidence of chronic diseases such as cancer and increased awareness of cancer early diagnosis and care in the area. In addition, increased government R&D spending is expected to help peptide therapeutics retain their domination in the coming years. The region's well-established biopharmaceutical and pharmaceutical industries are significant drivers of growth. Due to factors such as a rising number of research projects in the medical sector and an increasing number of diseases globally, the United States has the largest market share in the North American region, which is expected to rapid growth in this region.

Due to high untapped opportunities, low raw material costs, a rising base of companies offering outsourcing services, a growing biotech industry, and increasing R&D investments, the Asia Pacific peptide therapeutics market is projected to expand significantly. In addition, cheaper raw materials and the expiration of patents on blockbuster products are likely to fuel the generic market in the near future, providing major growth opportunities.

KEY MARKET PARTICIPANTS:

Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Novo Nordisk A/S., Novartis AG, Zealand Pharma AG, AmbioPharm Inc., Bachem Holding AG, PolyPeptide Group, Sanofi SA, Amylin Pharmaceuticals, CirclePharma, Inc., PeptiDream Inc., Apitope Technology, Arch NioPartners, and Galena Biopharmaceuticals are some of the prominent companies operating in the global peptide therapeutics market.

RECENT MARKET DEVELOPMENTS:

  • Leidos Health Life Sciences obtained a peptide for a novel PD-1 checkpoint inhibitor in January 2019. Under the Patents 4 Patients scheme of the United States Patent and Trademark Office, the patent was granted quickly. This service expedites the analysis of patent applications applicable to cancer immunotherapy.
  • CohBar, Inc. revealed additional preclinical evidence supporting the therapeutic efficacy of a novel CohBar peptide in a preclinical form of Idiopathic Pulmonary Fibrosis in December 2019. (IPF).
  • In December 2020, Takeda Pharmaceutical Company Limited and PeptiDream Inc. agreed to collaborate on research and produce peptide-drug conjugates (PDCs) for neuromuscular diseases under an exclusive license agreement.
  • Emgality, a subcutaneously administered calcitonin gene-related peptide (CGRP) antibody, was approved by the FDA in June 2019 for migraine prevention and the treatment of episodic cluster headache.
  1. Introduction                                                          
    1. Market Definition                                               
    2. Scope of the report                                            
    3. Study Assumptions                                            
    4. Base Currency, Base Year and Forecast Periods                                                     
  2. Research Methodology                                                                    
    1. Analysis Design                                                   
    2. Research Phases                                                 
      1. Secondary Research                                       
      2. Primary Research                              
      3. Data Modelling                                 
      4. Expert Validation                              
    3. Study Timeline                                                    
  3. Report Overview                                                                 
    1. Executive Summary                                           
    2. Key Inferences                                                  
  4. Market Dynamics                                                                
    1. Impact Analysis                                                   
      1. Drivers                                  
      2. Restraints                              
      3. Opportunities                                    
    2. Regulatory Environment                                                  
    3. Technology Timeline & Recent Trends                                                      
  5. Competitor Benchmarking Analysis                                                             
    1. Key Player Benchmarking                                                
      1. Market share analysis                                    
      2. Products/Service                              
      3. Regional Presence                            
    2. Mergers & Acquisition Landscape                                                
    3. Joint Ventures & Collaborations                                                  
  6. Market Segmentation                                                                       
    1. Peptide Therapeutics Market, By Type
      1. Generic
      2. Innovative
      3. Market Size Estimations & Forecasts (2021-2026)                               
      4. Y-o-Y Growth Rate Analysis                                         
      5. Market Attractiveness Index                                       
    2. Peptide Therapeutics Market, By Application                                  
      1. Metabolic
      2. Cardiovascular Disorder
      3. Respiratory
      4. GIT
      5. Anti-infection
      6. Pain
      7. Dermatology
      8. CNS
      9. Renal
      10. Others
      11. Market Size Estimations & Forecasts (2021-2026)                               
      12. Y-o-Y Growth Rate Analysis                                         
      13. Market Attractiveness Index       
    3. Peptide Therapeutics Market, By Type of Manufacturers 
      1. In-house
      2. Outsourced
      3. Market Size Estimations & Forecasts (2021-2026)                               
      4. Y-o-Y Growth Rate Analysis                                         
      5. Market Attractiveness Index       
    4. Peptide Therapeutics Market, By Route of Administration
      1. Parenteral Route
      2. Oral Route
      3. Pulmonary
      4. Mucosal
      5. Others
      6. Market Size Estimations & Forecasts (2021-2026)                               
      7. Y-o-Y Growth Rate Analysis                                         
      8. Market Attractiveness Index       
    5. Peptide Therapeutics Market, By Synthesis Technology
      1. Solid Phase Peptide Synthesis (SPPS)
      2. Liquid Phase Peptide Synthesis (LPPS)
      3. Hybrid Technology
      4. Market Size Estimations & Forecasts (2021-2026)                               
      5. Y-o-Y Growth Rate Analysis                                         
      6. Market Attractiveness Index       
  7. Geographical Landscape                                                                  
    1. Global Peptide Therapeutics Market, by Region                                            
    2. North America - Market Analysis (2021 to 2026)                                                      
      1. By Country                                         
        1. USA                      
        2. Canada               
    3. Europe                                                   
      1. By Country                                         
        1. UK                        
        2. France                 
        3. Germany                          
        4. Spain                   
        5. Italy                     
        6. Rest of Europe                 
    4. Asia Pacific                                             
      1. By Country                                         
        1. China                  
        2. India                    
        3. Japan                  
        4. South Korea                     
        5. South East Asia                
        6. Australia & NZ                  
        7. Rest of Asia-Pacific                        
    5. Latin America                                                      
      1. By Country                                         
        1. Brazil                   
        2. Argentina                         
        3. Mexico                
        4. Rest of Latin America                   
    6. Middle East and Africa                                                     
      1. By Country                                         
        1. Middle East                      
        2. Africa                  
  8. Key Player Analysis                                                             
    1. Eli Lilly and Company
      1. Business Description                                      
      2. Products/Service                              
      3. Financials                             
      4. SWOT Analysis                                  
      5. Recent Developments                                    
      6. Analyst Overview                              
    2. Amgen, Inc.
    3. Pfizer, Inc.
    4. Bristol-Myers Squibb Company
    5. Ever Neuro Pharma GmbH
    6. Takeda Pharmaceutical Company Limited
    7. AstraZeneca PLC
    8. GlaxoSmithKline plc
    9. Novo Nordisk A/S.
    10. Novartis AG
    11. Zealand Pharma AG
    12. AmbioPharm Inc.
    13. Bachem Holding AG
    14. PolyPeptide Group
    15. Sanofi SA
    16. Amylin Pharmaceuticals
    17. CirclePharma, Inc.
    18. PeptiDream Inc.
    19. Apitope Technology
    20. Arch NioPartners
    21. Galena Biopharmaceuticals
  9. Market Outlook & Investment Opportunities                                                          
  10. Appendix                                               
    1. List of Tables
    2. List of Figures
  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of type, application, type of manufacturers, route of administration and synthesis technology along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Global Peptide Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  3. Global Generic Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Innovative Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  6. Global Metabolic Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Cardiovascular Disorder Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global Respiratory Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global GIT Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global Anti-infection Market, By Region, From 2021 to 2026 (USD Billion)
  11. Global Pain Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Dermatology Market, By Region, From 2021 to 2026 (USD Billion)
  13. Global CNS Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global Renal Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  16. Global Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  17. Global In-house Market, By Region, From 2021 to 2026 (USD Billion)
  18. Global Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  19. Global Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  20. Global Parenteral Route Market, By Region, From 2021 to 2026 (USD Billion)
  21. Global Oral Route Market, By Region, From 2021 to 2026 (USD Billion)
  22. Global Pulmonary Market, By Region, From 2021 to 2026 (USD Billion)
  23. Global Mucosal Market, By Region, From 2021 to 2026 (USD Billion)
  24. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  25. Global Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  26. Global Solid Phase Peptide Synthesis (SPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  27. Global Liquid Phase Peptide Synthesis (LPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  28. Global Hybrid Technology Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  30. North America Generic Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Innovative Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  33. North America Metabolic Market, By Region, From 2021 to 2026 (USD Billion)
  34. North America Cardiovascular Disorder Market, By Region, From 2021 to 2026 (USD Billion)
  35. North America Respiratory Market, By Region, From 2021 to 2026 (USD Billion)
  36. North America GIT Market, By Region, From 2021 to 2026 (USD Billion)
  37. North America Anti-infection Market, By Region, From 2021 to 2026 (USD Billion)
  38. North America Pain Market, By Region, From 2021 to 2026 (USD Billion)
  39. North America Dermatology Market, By Region, From 2021 to 2026 (USD Billion)
  40. North America CNS Market, By Region, From 2021 to 2026 (USD Billion)
  41. North America Renal Market, By Region, From 2021 to 2026 (USD Billion)
  42. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  43. North America Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  44. North America In-house Market, By Region, From 2021 to 2026 (USD Billion)
  45. North America Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  46. North America Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  47. North America Parenteral Route Market, By Region, From 2021 to 2026 (USD Billion)
  48. North America Oral Route Market, By Region, From 2021 to 2026 (USD Billion)
  49. North America Pulmonary Market, By Region, From 2021 to 2026 (USD Billion)
  50. North America Mucosal Market, By Region, From 2021 to 2026 (USD Billion)
  51. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  52. North America Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  53. North America Solid Phase Peptide Synthesis (SPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  54. North America Liquid Phase Peptide Synthesis (LPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  55. North America Hybrid Technology Market, By Region, From 2021 to 2026 (USD Billion)
  56. United States Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  57. United States Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  58. United States Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  59. United States Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  60. United States Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  61. Canada Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  62. Canada Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  63. Canada Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  64. Canada Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  65. Canada Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  66. Europe Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  67. Europe Generic Market, By Region, From 2021 to 2026 (USD Billion)
  68. Europe Innovative Market, By Region, From 2021 to 2026 (USD Billion)
  69. Europe Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  70. Europe Metabolic Market, By Region, From 2021 to 2026 (USD Billion)
  71. Europe Cardiovascular Disorder Market, By Region, From 2021 to 2026 (USD Billion)
  72. Europe Respiratory Market, By Region, From 2021 to 2026 (USD Billion)
  73. Europe GIT Market, By Region, From 2021 to 2026 (USD Billion)
  74. Europe Anti-infection Market, By Region, From 2021 to 2026 (USD Billion)
  75. Europe Pain Market, By Region, From 2021 to 2026 (USD Billion)
  76. Europe Dermatology Market, By Region, From 2021 to 2026 (USD Billion)
  77. Europe CNS Market, By Region, From 2021 to 2026 (USD Billion)
  78. Europe Renal Market, By Region, From 2021 to 2026 (USD Billion)
  79. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  80. Europe Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  81. Europe In-house Market, By Region, From 2021 to 2026 (USD Billion)
  82. Europe Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  83. Europe Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  84. Europe Parenteral Route Market, By Region, From 2021 to 2026 (USD Billion)
  85. Europe Oral Route Market, By Region, From 2021 to 2026 (USD Billion)
  86. Europe Pulmonary Market, By Region, From 2021 to 2026 (USD Billion)
  87. Europe Mucosal Market, By Region, From 2021 to 2026 (USD Billion)
  88. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  89. Europe Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  90. Europe Solid Phase Peptide Synthesis (SPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  91. Europe Liquid Phase Peptide Synthesis (LPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  92. Europe Hybrid Technology Market, By Region, From 2021 to 2026 (USD Billion)
  93. U.K. Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  94. U.K. Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  95. U.K. Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  96. U.K. Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  97. U.K. Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  98. Germany Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  99. Germany Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  100. Germany Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  101. Germany Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  102. Germany Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  103. France Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  104. France Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  105. France Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  106. France Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  107. France Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  108. Italy Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  109. Italy Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  110. Italy Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  111. Italy Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  112. Italy Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  113. Spain Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  114. Spain Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  115. Spain Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  116. Spain Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  117. Spain Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  118. Asia Pacific Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  119. Asia Pacific Generic Market, By Region, From 2021 to 2026 (USD Billion)
  120. Asia Pacific Innovative Market, By Region, From 2021 to 2026 (USD Billion)
  121. Asia Pacific Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  122. Asia Pacific Metabolic Market, By Region, From 2021 to 2026 (USD Billion)
  123. Asia Pacific Cardiovascular Disorder Market, By Region, From 2021 to 2026 (USD Billion)
  124. Asia Pacific Respiratory Market, By Region, From 2021 to 2026 (USD Billion)
  125. Asia Pacific GIT Market, By Region, From 2021 to 2026 (USD Billion)
  126. Asia Pacific Anti-infection Market, By Region, From 2021 to 2026 (USD Billion)
  127. Asia Pacific Pain Market, By Region, From 2021 to 2026 (USD Billion)
  128. Asia Pacific Dermatology Market, By Region, From 2021 to 2026 (USD Billion)
  129. Asia Pacific CNS Market, By Region, From 2021 to 2026 (USD Billion)
  130. Asia Pacific Renal Market, By Region, From 2021 to 2026 (USD Billion)
  131. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  132. Asia Pacific Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  133. Asia Pacific In-house Market, By Region, From 2021 to 2026 (USD Billion)
  134. Asia Pacific Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  135. Asia Pacific Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  136. Asia Pacific Parenteral Route Market, By Region, From 2021 to 2026 (USD Billion)
  137. Asia Pacific Oral Route Market, By Region, From 2021 to 2026 (USD Billion)
  138. Asia Pacific Pulmonary Market, By Region, From 2021 to 2026 (USD Billion)
  139. Asia Pacific Mucosal Market, By Region, From 2021 to 2026 (USD Billion)
  140. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  141. Asia Pacific Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  142. Asia Pacific Solid Phase Peptide Synthesis (SPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  143. Asia Pacific Liquid Phase Peptide Synthesis (LPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  144. Asia Pacific Hybrid Technology Market, By Region, From 2021 to 2026 (USD Billion)
  145. Japan Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  146. Japan Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  147. Japan Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  148. Japan Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  149. Japan Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  150. China Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  151. China Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  152. China Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  153. China Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  154. China Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  155. India Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  156. India Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  157. India Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  158. India Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  159. India Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  160. Australia Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  161. Australia Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  162. Australia Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  163. Australia Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  164. Australia Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  165. South Korea Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  166. South Korea Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  167. South Korea Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  168. South Korea Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  169. South Korea Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  170. Latin America Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  171. Latin America Generic Market, By Region, From 2021 to 2026 (USD Billion)
  172. Latin America Innovative Market, By Region, From 2021 to 2026 (USD Billion)
  173. Latin America Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  174. Latin America Metabolic Market, By Region, From 2021 to 2026 (USD Billion)
  175. Latin America Cardiovascular Disorder Market, By Region, From 2021 to 2026 (USD Billion)
  176. Latin America Respiratory Market, By Region, From 2021 to 2026 (USD Billion)
  177. Latin America GIT Market, By Region, From 2021 to 2026 (USD Billion)
  178. Latin America Anti-infection Market, By Region, From 2021 to 2026 (USD Billion)
  179. Latin America Pain Market, By Region, From 2021 to 2026 (USD Billion)
  180. Latin America Dermatology Market, By Region, From 2021 to 2026 (USD Billion)
  181. Latin America CNS Market, By Region, From 2021 to 2026 (USD Billion)
  182. Latin America Renal Market, By Region, From 2021 to 2026 (USD Billion)
  183. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  184. Latin America Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  185. Latin America In-house Market, By Region, From 2021 to 2026 (USD Billion)
  186. Latin America Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  187. Latin America Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  188. Latin America Parenteral Route Market, By Region, From 2021 to 2026 (USD Billion)
  189. Latin America Oral Route Market, By Region, From 2021 to 2026 (USD Billion)
  190. Latin America Pulmonary Market, By Region, From 2021 to 2026 (USD Billion)
  191. Latin America Mucosal Market, By Region, From 2021 to 2026 (USD Billion)
  192. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  193. Latin America Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  194. Latin America Solid Phase Peptide Synthesis (SPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  195. Latin America Liquid Phase Peptide Synthesis (LPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  196. Latin America Hybrid Technology Market, By Region, From 2021 to 2026 (USD Billion)
  197. Brazil Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  198. Brazil Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  199. Brazil Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  200. Brazil Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  201. Brazil Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  202. Argentina Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  203. Argentina Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  204. Argentina Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  205. Argentina Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  206. Argentina Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  207. Mexico Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  208. Mexico Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  209. Mexico Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  210. Mexico Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  211. Mexico Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  212. Rest of Latin America Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  213. Rest of Latin America Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  214. Rest of Latin America Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  215. Rest of Latin America Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  216. Rest of Latin America Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  217. Middle East and Africa Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  218. Middle East and Africa Generic Market, By Region, From 2021 to 2026 (USD Billion)
  219. Middle East and Africa Innovative Market, By Region, From 2021 to 2026 (USD Billion)
  220. Middle East and Africa Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  221. Middle East and Africa Metabolic Market, By Region, From 2021 to 2026 (USD Billion)
  222. Middle East and Africa Cardiovascular Disorder Market, By Region, From 2021 to 2026 (USD Billion)
  223. Middle East and Africa Respiratory Market, By Region, From 2021 to 2026 (USD Billion)
  224. Middle East and Africa GIT Market, By Region, From 2021 to 2026 (USD Billion)
  225. Middle East and Africa Anti-infection Market, By Region, From 2021 to 2026 (USD Billion)
  226. Middle East and Africa Pain Market, By Region, From 2021 to 2026 (USD Billion)
  227. Middle East and Africa Dermatology Market, By Region, From 2021 to 2026 (USD Billion)
  228. Middle East and Africa CNS Market, By Region, From 2021 to 2026 (USD Billion)
  229. Middle East and Africa Renal Market, By Region, From 2021 to 2026 (USD Billion)
  230. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  231. Middle East and Africa Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  232. Middle East and Africa In-house Market, By Region, From 2021 to 2026 (USD Billion)
  233. Middle East and Africa Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  234. Middle East and Africa Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  235. Middle East and Africa Parenteral Route Market, By Region, From 2021 to 2026 (USD Billion)
  236. Middle East and Africa Oral Route Market, By Region, From 2021 to 2026 (USD Billion)
  237. Middle East and Africa Pulmonary Market, By Region, From 2021 to 2026 (USD Billion)
  238. Middle East and Africa Mucosal Market, By Region, From 2021 to 2026 (USD Billion)
  239. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  240. Middle East and Africa Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  241. Middle East and Africa Solid Phase Peptide Synthesis (SPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  242. Middle East and Africa Liquid Phase Peptide Synthesis (LPPS) Market, By Region, From 2021 to 2026 (USD Billion)
  243. Middle East and Africa Hybrid Technology Market, By Region, From 2021 to 2026 (USD Billion)
  244. Middle East Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  245. Middle East Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  246. Middle East Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  247. Middle East Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  248. Middle East Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)
  249. Africa Peptide Therapeutics Market, By Type, From 2021 to 2026 (USD Billion)
  250. Africa Peptide Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)
  251. Africa Peptide Therapeutics Market, By Type of Manufacturers, From 2021 to 2026 (USD Billion)
  252. Africa Peptide Therapeutics Market, By Route of Administration, From 2021 to 2026 (USD Billion)
  253. Africa Peptide Therapeutics Market, By Synthesis Technology, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample